InCarda Therapeutics Provides Corporate Update Highlighting Fundraising and Clinical Development Milestones
November 08, 2018 08:05 ET
|
InCarda Therapeutics, Inc.
Oversubscribed $42 Million Series B Financing Provides Significant Runway to Support Continued Advancement of Innovative Inhaled Cardiovascular Therapy First Patients Dosed in Phase 2 Clinical Trial...